Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Association of calcium channel blockers use with visual field progression in glaucoma clinics
Author Affiliations & Notes
  • Giovanni Montesano
    Optometry and Visual Sciences, City University of London, London, United Kingdom
    NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust, London, London, United Kingdom
  • Alessandro Rabiolo
    Department of Health Sciences, Universita degli Studi del Piemonte Orientale Amedeo Avogadro, Vercelli, Piemonte, Italy
    Eye Clinic, Azienda Ospedaliero Universitaria Maggiore della Carita, Novara, Piemonte, Italy
  • David F Garway-Heath
    NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust, London, London, United Kingdom
    Institute of Ophthalmology, University College London, London, United Kingdom
  • Dun Jack Fu
    NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust, London, London, United Kingdom
  • Gus Gazzard
    NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust, London, London, United Kingdom
    Institute of Ophthalmology, University College London, London, United Kingdom
  • Giovanni Ometto
    Optometry and Visual Sciences, City University of London, London, United Kingdom
    Institute of Ophthalmology, University College London, London, United Kingdom
  • David P. Crabb
    Optometry and Visual Sciences, City University of London, London, United Kingdom
  • Anthony P Khawaja
    NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust, London, London, United Kingdom
    Institute of Ophthalmology, University College London, London, United Kingdom
  • Footnotes
    Commercial Relationships   Giovanni Montesano Alcon, CenterVue-iCare, Omikron, Code C (Consultant/Contractor), Relayer, LtD, Code O (Owner), Alcon, Code R (Recipient); Alessandro Rabiolo None; David Garway-Heath AbbVie, Omikron, Santen, Roche, Carl Zeiss Meditec, CenterVue-iCare, Code C (Consultant/Contractor), Heidelberg Engineering, Santen, Janssen , Code F (Financial Support), T4, Moorfields MDT, ANSWERS, Visual Field Sensitivity Testing, Code P (Patent), Viatris, Omikron, Novartis, AbbVie, Code R (Recipient), European Glaucoma Society, Glaucoma Research Society, Code S (non-remunerative); Dun Jack Fu None; Gus Gazzard Alcon, Allergan/Abvie, Belkin Vision, Elios Vision, Genentech/Roche, Glaukos Corporation, McKinsey Consulting, Rayner, Reichert, Ripple Therapeutics, Santen, Sight Sciences, Thea, Vialase, Visufarma, Zeiss, Code C (Consultant/Contractor), NIHR-HTA, NIHR-EME, NIHE-RfPB, MRC (EAGLE trial), City University, European Glaucoma Society, Fight for Sight, British Council for Prevention of Blindness, Moorfields Eye Charity, Friends of Moorfields Charity, IGA-UK Royal College of Ophthalmologists, UKEGS, US-NIH (NEI), Code F (Financial Support), Alcon, Allergan/Abvie, Bausch & Lomb, Glaukos Corporation, Haag-Streit Group, Lumenis, Lumibird/Quantel/Ellex, Merck & Co, Reichert, Thea, Visufarma, Code R (Recipient); Giovanni Ometto Alcon, Code C (Consultant/Contractor), Relayer, LtD, Code O (Owner); David Crabb Apellis, Code C (Consultant/Contractor), Santen, Code F (Financial Support), Santen, Allergan/Abbvie, Janssen, Thea, Code R (Recipient); Anthony Khawaja Abbvie, Aerie, Allergan, Google Health, Heidelberg Engineering, Novartis, Reichert, Santen, Thea, Topcon, Code C (Consultant/Contractor)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 2763. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Giovanni Montesano, Alessandro Rabiolo, David F Garway-Heath, Dun Jack Fu, Gus Gazzard, Giovanni Ometto, David P. Crabb, Anthony P Khawaja; Association of calcium channel blockers use with visual field progression in glaucoma clinics. Invest. Ophthalmol. Vis. Sci. 2024;65(7):2763.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate the relationship between exposure to systemic calcium channel blockers (CCBs) and visual field (VF) progression in a large patient cohort.

Methods : We extracted VF data, demographics, and systemic medication information for 73,990 patients from five glaucoma clinics in England. VFs performed after incisional glaucoma surgery were excluded. We selected eyes with ≥ 5 reliable 24-2 SITA VFs (false positive rate < 15%) over ≥4 years and ≥2 tests with VF loss as estimated by Mean Deviation (MD) < -2 dB. We randomly selected one eye per patient (14,475 eyes; 133,505 tests) and identified 1,426 patients exposed to CCBs. We studied the effect of CCB exposure on MD progression with a Linear Mixed Model (LMM), with random intercepts and slopes. The MD was the response variable. The interaction between CCB exposure (dichotomous) and time (continuous) modeled the difference in rate of progression (RoP) between exposed and non-exposed. For our main analysis, we compared the exposed group to a control group, selected through multivariable (MV) propensity score (PS) matching. A secondary analysis was performed with a MV-LMM on the whole cohort; as for the main LMM, interactions between the additional predictors and time modeled their effect on RoP. Variables in the PS and MV-LMM, selected via a causal diagram, are reported in the Figure.

Results : Participant demographics are reported in the Table. CCB users had a slower RoP (Estimate [95%-Confidence Interval]: -0.29 [-0.32, -0.27] dB/year) compared to PS-matched controls (-0.34 [-0.37, -0.31] dB/year, p = 0.022). The results from the MV-LMM are shown in the forest plot in the Figure and confirmed the association between CCB exposure and faster RoP (p = 0.0006). Anti-hypertensives (other than nitrates and systemic beta-blockers) were also significantly associated with slower RoP. Systemic corticosteroids were associated with faster RoP. Older age and more positive baseline MD and Pattern Standard Deviation were associated with faster RoP . Female sex was associated with a slower RoP. The association with race was not significant, but this cohort was 98% white.

Conclusions : In this large clinical cohort, CCB exposure was significantly associated with a slower VF deterioration rate, after multivariable adjustment. Further studies are needed to replicate this finding and elucidate the mechanistic link between glaucoma progression and CCBs.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×